$Alzamend Neuro(ALZN.US$ EXCLUSIVE: Alzamend Neuro Tells Benzinga Co. Announces Agreement For Registered Direct Offering And Concurrent Private Placement For An Aggregate Of Up To $25M
$Virios Therapeutics(VIRI.US$ Virios Therapeutics - Discussions Are Ongoing as We Seek a Partner to Advance Imc-1 Into Phase 3 Development for Treatment of Fm
2
Trytosaveabit
commented on
$BioCryst Pharmaceuticals(BCRX.US$ Benzinga· 1 min BioCryst Presents New Real-world Evidence Showing Significant Reductions In Healthcare Resource Utilization Among Patients With Hereditary Angioedema Following Initiation Of Orladeyo (Berotralstat
2
Trytosaveabit
liked
$Pop Culture(CPOP.US$
Take note 113% year-on-year revenue growth!
Take note 113% year-on-year revenue growth!
1
$Pop Culture(CPOP.US$ Break 3.25? will look for 3.43 and 3.85 NFA
2
3
$Aslan Pharmaceuticals(ASLN.US$ Anticipated upcoming milestones
•Late breaking poster presentation of positive translational data from a head-to-head study of eblasakimab versus dupilumab in a human tissue model of COPD at the American Thoracic Society International Conference 2024 on May 20, 2024 •Topline interim data from the farudodstat Phase 2a study in AA expected in Q3 2024•Topline data from the TREK-DX trial of eblasakimab expected at the end of 2024•Selection of a dev...
•Late breaking poster presentation of positive translational data from a head-to-head study of eblasakimab versus dupilumab in a human tissue model of COPD at the American Thoracic Society International Conference 2024 on May 20, 2024 •Topline interim data from the farudodstat Phase 2a study in AA expected in Q3 2024•Topline data from the TREK-DX trial of eblasakimab expected at the end of 2024•Selection of a dev...
2
$bluebird bio(BLUE.US$ Reuters· 1 min ago
Bluebird bio Inc - Anticipates Recognizing Revenue From Its First Infusion of Lyfgenia in Q3 of 2024
Bluebird bio Inc - Anticipates Recognizing Revenue From Its First Infusion of Lyfgenia in Q3 of 2024
Trytosaveabit
liked
$TScan Therapeutics(TCRX.US$
NEWS
TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
NEWS
TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
1
$TScan Therapeutics(TCRX.US$ TScan Therapeutics Inc - on-Track to Report Initial Data From Solid Tumor Clinical Trial in 2024
1